225P - Clinical outcomes of single versus double hormone receptor positive breast cancer patients treated with neoadjuvant chemotherapy

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cytotoxic agents
Breast Cancer
Therapy
Biological therapy
Presenter Jacques Raphael
Citation Annals of Oncology (2017) 28 (suppl_5): v68-v73. 10.1093/annonc/mdx364
Authors J. Raphael1, S. Nofech-Mozes2, M. Trudeau1
  • 1Department Of Medicine, Division Of Medical Oncology, Sunnybrook Health Sciences Centre, M4N 3M5 - Toronto/CA
  • 2Department Of Pathology, Sunnybrook Health Sciences Centre, M4N 3M5 - Toronto/CA

Abstract

Background

This study aimed to evaluate and compare tumor response rates and survival outcomes between single and double hormone receptor (HR) positive (+) [Estrogen Receptor (ER+)/Progesterone Receptor (PR) negative (-) or ER-/PR+ versus ER+/PR+] breast cancer (BC) patients with any HER2 status treated with neoadjuvant chemotherapy at a single institution.

Methods

A retrospective review was conducted using the Sunnybrook “Biomatrix” database to identify eligible patients. A multivariable logistic regression analysis (MLR) was performed to assess the association between HR status (single or double HR+) and pathologic complete response (pCR) rates at surgery. A Kaplan-Meier method was used to estimate Disease Free Survival (DFS) and a log-rank test was used to compare DFS between 3 subgroups of patients: single or double HR+ and HR negative patients.

Results

Three hundred and four BC patients were identified and included in the analysis with a median follow up of 43.3 months (Q1-Q3: 28.7-61.1) and a mean age of 49.7 years (Standard deviation 10.9). Forty seven percent (47/101), 31% (11/36) and 14% (24/167) of patients with HR negative, single HR+ and double HR+ disease achieved a pCR respectively (X2 test

Conclusions

BC patients with single HR+ disease behave differently than double HR+ patients in terms of likelihood of achieving pCR after neoadjuvant chemotherapy and do not differ from HR negative patients. This difference does not translate into a difference in DFS. Prospective studies are needed to validate these findings before considering different treatment strategies for these 2 subgroups of HR+ BC patients.

Clinical trial identification

Legal entity responsible for the study

Jacques Raphael

Funding

None

Disclosure

All authors have declared no conflicts of interest.